Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis
Year: 2011
Type: article
Study design: Observational Study
Abstract: Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.
Source: Blood
Authors: Mukta Arora, John P. Klein, Daniel J. Weisdorf, Anna Hassebroek, Mary E. D. Flowers, Corey S. Cutler, Alvaro Urbano-Ispizua, Joseph H. Antin, Brian J. Bolwell, Michael Boyiadzis, Jean-Yves Cahn, Mitchell S. Cairo, Luis Isola, David A. Jacobsohn, Madan Jagasia, Thomas R. Klumpp, Stephanie J. Lee, Effie W. Petersdorf, Stella Santarone, Robert Peter Gale, Harry C. Schouten, Stephen Spellman, John R. Wingard, Mary M. Horowitz, Steven Z. Pavletic
Institutions: University of Minnesota, Medical College of Wisconsin, National Marrow Donor Program, University of Washington, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Hospital Clínic de Barcelona, Cleveland Clinic, UPMC Hillman Cancer Center, Centre Hospitalier Universitaire de Grenoble, Morgan Stanley Children's Hospital, Columbia University, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, Children's National, Vanderbilt University, Vanderbilt University Medical Center, Temple University, Azienda USL di Pescara, Celgene (United States), Maastricht University Medical Centre, University of Florida Health, University of Florida, UF Health Cancer Center, National Cancer Institute, Center for Cancer Research
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, Be The Match Foundation, Amgen, Pfizer, Astellas Pharma US, WellPoint, Biogen, Viropharma, Celgene, HistoGenetics, Osiris Therapeutics, Therakos, Blue Cross and Blue Shield Association, BioMarin Pharmaceutical, StemCyte, Medical College of Wisconsin, Sigma-Tau Pharmaceuticals, Otsuka America, CellGenix, Eisai, Astellas Pharma, National Institutes of Health, Health Resources and Services Administration, Genentech, U.S. Navy, Takeda Oncology, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Awards: G327847204, G3609734018, G3822637944, G3939980515, G4928541993, G5080983006, G5393820452, G5685110365, G5699415455, G6749775408, BMT Clinical Research Network Data Coordinating Center, G7020281871, G8107732965, G833124618, G8876996369, G894505544, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research, G909763084
OpenAlex ID: W2080200044